With the IND approval, APX001/SSS07 will be studied in clinical trials for the treatment of autoimmune and inflammatory diseases.
Apexigen president and CEO Dr. Xiaodong Yang said, "It represents the hard work of many individuals working collaboratively as a team to achieve the common goal. We look forward to continuing success in our collaboration."
APX001/SSS07 was discovered by leveraging Apexigen’s monoclonal antibody technologies and was developed by 3SBio in China under a license from Apexigen.
APX001 is the second antibody discovered through the use of Apexigen’s technologies for which an IND has been filed with the SFDA.